“…The sample size ranged from 14 to 159 participants, with a mean age of 60.9 ± 20.0 years, varying from 7.9 years to 83.2 years. With regard to the adult population, 16 studies evaluated the effects of WBV in the elderly ( n = 59.8 ± 35.4 subjects) (9, 30–32, 36, 40, 44, 45, 50, 53, 55, 56, 59, 62, 64, 69), four in patients with Chronic Obstructive Pulmonary Disease (COPD) ( n = 42.5 ± 16.7 subjects) (57, 61, 65, 71), seven in patients with stroke ( n = 46.1 ± 27.2 subjects) (28, 35, 38, 51, 54, 67, 72), four in patients with osteoarthritis (OA) ( n = 32.2 ± 11.9 subjects) (29, 33, 63, 68), three in postmenopausal women ( n = 40.3 ± 12.5 subjects) (48, 58, 66), two in patients with multiple sclerosis ( n = 29.5 ± 6.3 subjects) (34, 39) and one in patients with the following pathologies: incomplete cervical spinal injury (47), pulmonary arterial hypertension (42), lung transplantation (43), idiopathic Parkinson's disease (41), total knee arthroplasty (49) and cerebral palsy (27) ( n = 30.0 ± 26.4 subjects). With regard to the child population, two studies evaluated the effects of WBV in cerebral palsy (37, 60), one in patients with osteogenesis imperfect (46) and one in patients with spastic diplegia or quadriplegia forms of cerebral palsy (52) ( n = 22.5 ± 5.9 subjects).…”